Advantage Alpha Capital Partners LP Has $523,000 Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Advantage Alpha Capital Partners LP cut its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 34.2% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,379 shares of the biopharmaceutical company’s stock after selling 11,651 shares during the period. Advantage Alpha Capital Partners LP’s holdings in TG Therapeutics were worth $523,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. NBC Securities Inc. boosted its stake in TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 485 shares in the last quarter. Quarry LP lifted its holdings in shares of TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 503 shares during the last quarter. Private Advisor Group LLC boosted its stake in shares of TG Therapeutics by 3.9% in the 3rd quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 542 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of TG Therapeutics by 127.3% in the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 849 shares in the last quarter. Finally, KBC Group NV increased its position in TG Therapeutics by 30.5% during the 3rd quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,092 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Transactions at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This trade represents a 4.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 10.50% of the company’s stock.

TG Therapeutics Stock Down 1.0 %

Shares of NASDAQ:TGTX opened at $34.26 on Wednesday. The firm has a market cap of $5.33 billion, a P/E ratio of -342.60 and a beta of 2.19. TG Therapeutics, Inc. has a 12-month low of $12.30 and a 12-month high of $36.84. The business has a fifty day simple moving average of $25.81 and a 200 day simple moving average of $21.83. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same period in the prior year, the firm earned $0.73 earnings per share. TG Therapeutics’s revenue was down 49.4% compared to the same quarter last year. Analysts predict that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. The Goldman Sachs Group raised their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. raised their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a report on Monday. HC Wainwright boosted their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. B. Riley increased their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $50.00 price target on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.